Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Easy Mark who wrote (345)	4/3/1998 5:58:00 PM
From: Steve Lokness	Read Replies (1) \| Respond to of 1510

Easy Mark; You obviously know much more of this subject than I do, however I do not understand your statement "why should CEGE's technology be useful". Are you saying CEGE's technology is flawed? Also as I was just reading the CEGE annual report, I was also struck by your statement re: the inability of CEGE's technology to recognize HIV mutates - am I reading your post correctly? Their report (CEGE's) mentions that this is one of the advantages of the CEGE technology - that is that it does recognize mutated HIV strains. If you believe this to be wrong and can give reasons as to -why - I would appreciate hearing. Sorry to stray here a little, but an interesting company with a huge potential is VGINF. This Canadian company test for mutated HIV strains with new fast and cheap genetic test that sure looks to have a lot of potential. Steve